Evaluation of the safety and efficacy of ivonescimab in combination with ligufalimab as first-line (1L) treatment for PD-L1 positive recurrent/metastasis head and neck squamous cell carcinoma (R/M HNSCC)
机构：[1]Zhejiang Canc Hosp, Head & Neck Radiotherapy Dept, Hangzhou, Peoples R China浙江省肿瘤医院[2]Shandong First Med Univ, Shandong Canc Hosp, Canc Hosp, Head & Neck Radiotherapy Dept 2, Jinan, Peoples R China[3]Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Head & Neck Radiotherapy Dept 2,Xiangya Sch Med, Changsha, Peoples R China[4]Huazhong Univ Sci & Technolog, Tongji Med Coll, Union Hosp, Canc Ctr, Wuhan, Peoples R China华中科技大学同济医学院附属协和医院[5]Hebei Med Univ, Affiliated Hosp 4, Dept Radiotherapy, Shijiazhuang, Hebei, Peoples R China河北医科大学第四医院胸部放疗一病区临床科室[6]Akeso Biopharma Inc, Med Dept, Zhongshan, Peoples R China
第一作者机构：[1]Zhejiang Canc Hosp, Head & Neck Radiotherapy Dept, Hangzhou, Peoples R China
推荐引用方式(GB/T 7714)：
Chen X.,Hu M.,Jin T.,et al.Evaluation of the safety and efficacy of ivonescimab in combination with ligufalimab as first-line (1L) treatment for PD-L1 positive recurrent/metastasis head and neck squamous cell carcinoma (R/M HNSCC)[J].ANNALS OF ONCOLOGY.2024,35:S626-S627.doi:10.1016/j.annonc.2024.08.937.
APA：
Chen, X.,Hu, M.,Jin, T.,Teng, K.,Han, Y....&Xia, Y..(2024).Evaluation of the safety and efficacy of ivonescimab in combination with ligufalimab as first-line (1L) treatment for PD-L1 positive recurrent/metastasis head and neck squamous cell carcinoma (R/M HNSCC).ANNALS OF ONCOLOGY,35,
MLA：
Chen, X.,et al."Evaluation of the safety and efficacy of ivonescimab in combination with ligufalimab as first-line (1L) treatment for PD-L1 positive recurrent/metastasis head and neck squamous cell carcinoma (R/M HNSCC)".ANNALS OF ONCOLOGY 35.(2024):S626-S627
医学